BSX Stock Overview
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
Boston Scientific Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$41.20|
|52 Week High||US$47.50|
|52 Week Low||US$37.96|
|1 Month Change||-3.58%|
|3 Month Change||-8.65%|
|1 Year Change||-3.17%|
|3 Year Change||7.26%|
|5 Year Change||49.28%|
|Change since IPO||862.34%|
Recent News & Updates
BSX: Boston Scientific Sports Growth At A Reasonable Price
Healthcare stocks have beaten the S&P 500 so far this year with particular relative strength seen in Medical Device stocks. Boston Scientific features a reasonable earnings multiple, given a hearty growth outlook. Traders should wait for a breakout before jumping into this strong medical device large-cap stock.
Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
|BSX||US Medical Equipment||US Market|
Return vs Industry: BSX exceeded the US Medical Equipment industry which returned -14.9% over the past year.
Return vs Market: BSX exceeded the US Market which returned -10.2% over the past year.
|BSX Average Weekly Movement||4.7%|
|Medical Equipment Industry Average Movement||10.5%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||17.0%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: BSX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: BSX's weekly volatility (5%) has been stable over the past year.
About the Company
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.
Boston Scientific Fundamentals Summary
|BSX fundamental statistics|
Is BSX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BSX income statement (TTM)|
|Cost of Revenue||US$3.71b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.53|
|Net Profit Margin||6.22%|
How did BSX perform over the long term?See historical performance and comparison
Is Boston Scientific undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BSX ($41.2) is trading below our estimate of fair value ($53.69)
Significantly Below Fair Value: BSX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BSX is poor value based on its Price-To-Earnings Ratio (77.9x) compared to the US Medical Equipment industry average (36.3x).
PE vs Market: BSX is poor value based on its Price-To-Earnings Ratio (77.9x) compared to the US market (15.6x).
Price to Earnings Growth Ratio
PEG Ratio: BSX is poor value based on its PEG Ratio (2.1x)
Price to Book Ratio
PB vs Industry: BSX is overvalued based on its Price-To-Book Ratio (3.5x) compared to the US Medical Equipment industry average (2.5x).
How is Boston Scientific forecast to perform in the next 1 to 3 years based on estimates from 25 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BSX's forecast earnings growth (36.7% per year) is above the savings rate (1.9%).
Earnings vs Market: BSX's earnings (36.7% per year) are forecast to grow faster than the US market (13.2% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: BSX's revenue (7.1% per year) is forecast to grow slower than the US market (8.1% per year).
High Growth Revenue: BSX's revenue (7.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BSX's Return on Equity is forecast to be low in 3 years time (15.2%).
How has Boston Scientific performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BSX has a large one-off loss of $637.0M impacting its March 31 2022 financial results.
Growing Profit Margin: BSX's current net profit margins (6.2%) are higher than last year (2%).
Past Earnings Growth Analysis
Earnings Trend: BSX's earnings have grown by 12.7% per year over the past 5 years.
Accelerating Growth: BSX's earnings growth over the past year (276.1%) exceeds its 5-year average (12.7% per year).
Earnings vs Industry: BSX earnings growth over the past year (276.1%) exceeded the Medical Equipment industry 16.1%.
Return on Equity
High ROE: BSX's Return on Equity (4.8%) is considered low.
How is Boston Scientific's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: BSX's short term assets ($5.1B) exceed its short term liabilities ($4.3B).
Long Term Liabilities: BSX's short term assets ($5.1B) do not cover its long term liabilities ($11.3B).
Debt to Equity History and Analysis
Debt Level: BSX's net debt to equity ratio (53.6%) is considered high.
Reducing Debt: BSX's debt to equity ratio has reduced from 78.2% to 55.6% over the past 5 years.
Debt Coverage: BSX's debt is not well covered by operating cash flow (16.4%).
Interest Coverage: BSX's interest payments on its debt are well covered by EBIT (4x coverage).
What is Boston Scientific current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BSX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BSX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BSX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BSX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BSX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Mahoney (56 yo)
Mr. Michael F. Mahoney, also known as Mike, has been Chairman of Boston Scientific Corporation since May 3, 2016, and is its Chief Executive Officer since November 1, 2012 and has been its President since...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD16.06M) is about average for companies of similar size in the US market ($USD13.06M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
Experienced Management: BSX's management team is seasoned and experienced (8.4 years average tenure).
Experienced Board: BSX's board of directors are considered experienced (7.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Boston Scientific Corporation's employee growth, exchange listings and data sources
- Name: Boston Scientific Corporation
- Ticker: BSX
- Exchange: NYSE
- Founded: 1979
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$58.898b
- Shares outstanding: 1.43b
- Website: https://www.bostonscientific.com
Number of Employees
- Boston Scientific Corporation
- 300 Boston Scientific Way
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/28 00:00|
|End of Day Share Price||2022/05/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.